Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:DGX NASDAQ:EXAS NASDAQ:MYGN NASDAQ:NTRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDGXQuest Diagnostics$183.44+1.8%$175.29$146.17▼$185.62$20.52B0.54754,767 shs556,218 shsEXASExact Sciences$53.81+4.7%$48.73$38.81▼$72.83$10.19B1.053.24 million shs4.19 million shsMYGNMyriad Genetics$6.61-2.7%$5.41$3.76▼$29.30$615.03M1.931.40 million shs1.26 million shsNTRANatera$168.02+0.9%$154.35$110.57▼$183.00$23.06B1.681.21 million shs776,006 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDGXQuest Diagnostics+1.81%+0.89%+6.02%+5.13%+18.05%EXASExact Sciences+4.67%+13.48%+14.71%-1.93%-5.81%MYGNMyriad Genetics-2.65%+3.77%+16.58%+29.86%-73.94%NTRANatera+0.88%-0.14%+21.64%+2.60%+48.38%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDGXQuest Diagnostics$183.44+1.8%$175.29$146.17▼$185.62$20.52B0.54754,767 shs556,218 shsEXASExact Sciences$53.81+4.7%$48.73$38.81▼$72.83$10.19B1.053.24 million shs4.19 million shsMYGNMyriad Genetics$6.61-2.7%$5.41$3.76▼$29.30$615.03M1.931.40 million shs1.26 million shsNTRANatera$168.02+0.9%$154.35$110.57▼$183.00$23.06B1.681.21 million shs776,006 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDGXQuest Diagnostics+1.81%+0.89%+6.02%+5.13%+18.05%EXASExact Sciences+4.67%+13.48%+14.71%-1.93%-5.81%MYGNMyriad Genetics-2.65%+3.77%+16.58%+29.86%-73.94%NTRANatera+0.88%-0.14%+21.64%+2.60%+48.38%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDGXQuest Diagnostics 2.50Moderate Buy$186.001.40% UpsideEXASExact Sciences 2.88Moderate Buy$67.0524.61% UpsideMYGNMyriad Genetics 2.21Hold$12.4588.42% UpsideNTRANatera 3.06Buy$194.0015.46% UpsideCurrent Analyst Ratings BreakdownLatest MYGN, DGX, EXAS, and NTRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025EXASExact SciencesZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/2/2025NTRANateraRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$268.008/25/2025DGXQuest DiagnosticsBaird R WSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/25/2025DGXQuest DiagnosticsRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$194.008/15/2025NTRANateraStephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$183.008/12/2025EXASExact SciencesBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$65.00 ➝ $60.008/11/2025NTRANateraPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$210.00 ➝ $220.008/11/2025EXASExact SciencesPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$70.00 ➝ $60.008/10/2025NTRANateraMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$195.008/8/2025NTRANateraCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/8/2025NTRANateraBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$190.00 ➝ $210.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDGXQuest Diagnostics$9.87B2.08$13.50 per share13.59$61.38 per share2.99EXASExact Sciences$2.76B3.69$5.63 per share9.56$12.98 per share4.15MYGNMyriad Genetics$837.60M0.73$1.00 per share6.62$7.70 per share0.86NTRANatera$1.70B13.59N/AN/A$9.05 per share18.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDGXQuest Diagnostics$871M$8.3521.9717.492.439.01%15.24%6.64%10/28/2025 (Estimated)EXASExact Sciences-$1.03B-$5.43N/A107.625.50-34.19%-1.75%-0.76%11/4/2025 (Estimated)MYGNMyriad Genetics-$127.30M-$4.28N/AN/AN/A-47.45%-5.17%-3.44%11/6/2025 (Estimated)NTRANatera-$190.43M-$1.91N/AN/AN/A-12.89%-22.22%-15.03%11/11/2025 (Estimated)Latest MYGN, DGX, EXAS, and NTRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025NTRANatera-$0.60-$0.74-$0.14-$0.74$476.84 million$546.60 million8/6/2025Q2 2025EXASExact Sciences-$0.02$0.22+$0.24-$0.01$774.43 million$811.09 million7/22/2025Q2 2025DGXQuest Diagnostics$2.57$2.62+$0.05$2.47$2.73 billion$2.76 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDGXQuest Diagnostics$3.201.74%N/A38.32%14 YearsEXASExact SciencesN/AN/AN/AN/AN/AMYGNMyriad GeneticsN/AN/AN/AN/AN/ANTRANateraN/AN/AN/AN/AN/ALatest MYGN, DGX, EXAS, and NTRA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date8/13/2025DGXQuest Diagnosticsquarterly$0.801.79%10/3/202510/3/202510/20/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDGXQuest Diagnostics0.711.090.99EXASExact Sciences0.942.892.56MYGNMyriad GeneticsN/A1.421.28NTRANateraN/A3.723.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDGXQuest Diagnostics88.06%EXASExact Sciences88.82%MYGNMyriad Genetics99.02%NTRANatera99.90%Insider OwnershipCompanyInsider OwnershipDGXQuest Diagnostics8.16%EXASExact Sciences1.20%MYGNMyriad Genetics2.40%NTRANatera5.63%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDGXQuest Diagnostics56,000111.82 million102.70 millionOptionableEXASExact Sciences7,000189.32 million187.05 millionOptionableMYGNMyriad Genetics2,70093.04 million90.81 millionOptionableNTRANatera4,434137.25 million129.52 millionOptionableMYGN, DGX, EXAS, and NTRA HeadlinesRecent News About These CompaniesEFG Asset Management North America Corp. Sells 8,563 Shares of Natera, Inc. $NTRASeptember 6 at 8:55 AM | marketbeat.comSolomon Moshkevich Sells 3,000 Shares of Natera (NASDAQ:NTRA) StockSeptember 6 at 8:10 AM | insidertrades.comNatera, Inc. $NTRA Shares Purchased by AQR Capital Management LLCSeptember 6 at 7:01 AM | marketbeat.comNatera, Inc. $NTRA Shares Bought by Panagora Asset Management Inc.September 5 at 5:01 AM | marketbeat.comRowan Chapman Sells 2,750 Shares of Natera (NASDAQ:NTRA) StockSeptember 4 at 12:47 AM | marketbeat.comADAR1 Capital Management LLC Invests $601,000 in Natera, Inc. $NTRASeptember 4 at 7:41 AM | marketbeat.comMPM Bioimpact LLC Has $22.21 Million Holdings in Natera, Inc. $NTRASeptember 4 at 7:02 AM | marketbeat.comMagnetar Financial LLC Buys Shares of 2,669 Natera, Inc. $NTRASeptember 4 at 5:04 AM | marketbeat.comCanada Pension Plan Investment Board Acquires 63,200 Shares of Natera, Inc. $NTRASeptember 4 at 5:03 AM | marketbeat.comInsider Selling: Natera (NASDAQ:NTRA) Director Sells 2,750 Shares of StockSeptember 4 at 4:23 AM | americanbankingnews.comNatera, Inc. $NTRA Shares Sold by Kestra Advisory Services LLCSeptember 4 at 3:47 AM | marketbeat.comMaverick Capital Ltd. Buys 268,715 Shares of Natera, Inc. $NTRASeptember 3 at 7:29 AM | marketbeat.com3,095 Shares in Natera, Inc. $NTRA Acquired by B. Metzler seel. Sohn & Co. AGSeptember 3 at 4:47 AM | marketbeat.comNatera (NASDAQ:NTRA) Director Sells $459,222.50 in StockSeptember 3 at 4:23 AM | insidertrades.comTracking Stanley Druckenmiller's Duquesne Family Office Portfolio - Q2 2025 UpdateSeptember 2, 2025 | seekingalpha.comNatera price target raised to $268 from $255 at RBC CapitalSeptember 2, 2025 | msn.comNatera: A Buy As Positive Growth And Cashflow Outweigh UnprofitabilitySeptember 2, 2025 | seekingalpha.comNatera (NTRA) Provides an Update on its Intellectual Property Litigation With NeoGenomicsSeptember 2, 2025 | insidermonkey.comParnassus Investments LLC Purchases 49,546 Shares of Natera, Inc. $NTRASeptember 1, 2025 | marketbeat.comDriehaus Capital Management LLC Buys 21,539 Shares of Natera, Inc. $NTRAAugust 31, 2025 | marketbeat.comGordian Capital Singapore Pte Ltd Has $1.36 Million Stock Position in Natera, Inc. $NTRAAugust 31, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMYGN, DGX, EXAS, and NTRA Company DescriptionsQuest Diagnostics NYSE:DGX$183.44 +3.33 (+1.85%) Closing price 09/5/2025 03:59 PM EasternExtended Trading$183.28 -0.16 (-0.09%) As of 09/5/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.Exact Sciences NASDAQ:EXAS$53.81 +2.40 (+4.67%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$53.50 -0.31 (-0.58%) As of 09/5/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.Myriad Genetics NASDAQ:MYGN$6.61 -0.18 (-2.65%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$6.61 0.00 (0.00%) As of 09/5/2025 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.Natera NASDAQ:NTRA$168.02 +1.46 (+0.88%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$167.70 -0.31 (-0.19%) As of 09/5/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
